<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00424749</url>
  </required_header>
  <id_info>
    <org_study_id>06-004767</org_study_id>
    <secondary_id>UL1RR024150</secondary_id>
    <nct_id>NCT00424749</nct_id>
  </id_info>
  <brief_title>Rituxan in Churg Strauss Syndrome With Renal Involvement</brief_title>
  <official_title>A Pilot Study on the Use of Rituximab in the Treatment of Churg- Strauss Syndrome With Renal Involvement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fernando Fervenza</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Churg-Strauss Syndrome (CSS) is a disease characterized by asthma, abnormally high amounts of
      eosinophils (a type of white blood cell), and blood vessel inflammation. About 25% of CSS
      patients develop kidney disease. The goal of this pilot study was to evaluate the safety and
      effectiveness of Rituximab in inducing remission of kidney disease in patients with CSS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Churg-Strauss syndrome (CSS) is a small vessel systemic vasculitis associated with asthma and
      eosinophilia that causes glomerulonephritis in about 25% of patients. Rituximab is a chimeric
      anti-CD20 monoclonal antibody that depletes B cells and is effective in numerous autoimmune
      disease including antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. The aim
      of this study was to evaluate the safety and efficacy of Rituximab in inducing remission of
      renal disease activity in patients with CSS.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Company providing study drug terminated study due to lack of funds
  </why_stopped>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants With Remission of Renal Disease Activity at 3 Months</measure>
    <time_frame>3 months after beginning of remission induction regimen</time_frame>
    <description>Remission of renal disease activity was indicated by stable or falling creatinine, absence of active urinary sediment AND reduction of oral prednisone dose to less than 50% of average dose of preceding 3 months or less than 10 mg/day (whichever smaller)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participants With Normalization of Eosinophil Count at 6 Months</measure>
    <time_frame>6 months after beginning of remission induction regimen</time_frame>
    <description>Normalization of eosinophil counts was defined as total eosinophil counts &lt;1.5 x 10^9/L.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Churg-Strauss Syndrome</condition>
  <arm_group>
    <arm_group_label>Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>375 mg/m^2/week for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Patients received 4 weekly doses of rituximab 375 mg/m^2.</description>
    <arm_group_label>Rituximab</arm_group_label>
    <other_name>Rituxan</other_name>
    <other_name>MabThera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone 1 mg/kg/day (not to exceed 80 mg/day) for 4 weeks followed by a taper to 0 mg by 6 months</description>
    <arm_group_label>Rituximab</arm_group_label>
    <other_name>Deltasone</other_name>
    <other_name>Liquid Pred</other_name>
    <other_name>Meticorten</other_name>
    <other_name>Orasone</other_name>
    <other_name>Prednicen-M</other_name>
    <other_name>Prednicot</other_name>
    <other_name>Sterapred</other_name>
    <other_name>Sterapred DS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with Churg-Strauss syndrome as defined by meeting one of 3 sets of criteria
             for Churg-Strauss Syndrome described above who have not yet been treated, who have
             failed steroid therapy (partial or non-responders) or who can not been tapered off
             oral prednisone because of documented relapsing disease

          -  Renal involvement (&gt;25% dysmorphic red cell, red blood cell casts, or pauci-immune
             glomerulonephritis on biopsy)

          -  Age &gt;18 years old

          -  Serum creatinine less than or equal to 3.0 mg/dl

          -  Able and willing to give written informed consent and comply with the requirements of
             the study protocol.

          -  Negative serum pregnancy test (for women of child bearing age)

          -  Men and women of reproductive potential must agree to use an acceptable method of
             birth control during treatment and for twelve months after completion of treatment.

        Exclusion Criteria

          -  Severe obstructive or restrictive lung disease (forced expiratory volume in one second
             &lt;1)

          -  Cerebral involvement

          -  Rapidly progressive optic neuropathy or retinal vasculitis

          -  Active gastrointestinal bleeding

          -  Heart failure, including pericarditis or myocarditis.

          -  Hemoglobin &lt;8.5 gm/dL

          -  Platelets &lt;100,000/mm

          -  AST or ALT &gt;2.5 Upper Limit of Normal unless related to primary disease

          -  Positive Hepatitis B or C serology

          -  History of positive HIV testing

          -  Treatment with any investigational agent within 4 weeks of screening or 5 half-lives
             of the investigational drug (whichever is longer)

          -  Previous treatment with Rituximab

          -  History of severe allergic or anaphylactic reactions to humanized or murine monoclonal
             antibodies

          -  History of recurrent significant infection or history of recurrent bacterial
             infections

          -  Known active bacterial, viral fungal mycobacterial, or other infection (including
             tuberculosis or atypical mycobacterial disease, but excluding fungal infections of
             nail beds) or any major episode of infection requiring hospitalization or treatment
             with i.v. antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks
             prior to screening

          -  Lack of peripheral venous access

          -  History of drug, alcohol, or chemical abuse within 6 months prior to screening

          -  Pregnancy or lactation

          -  Concomitant malignancies or previous malignancies, with the exception of adequately
             treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the
             cervix

          -  Significant cardiac or pulmonary disease (including obstructive pulmonary disease)

          -  Any other disease, metabolic dysfunction, physical examination finding, or clinical
             laboratory finding giving reasonable suspicion of a disease or condition that
             contraindicates the use of an investigational drug or that may affect the
             interpretation of the results or render the patient at high risk from treatment
             complications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernando C. Fervenza, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicaltrials.mayo.edu</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <results_reference>
    <citation>Cartin-Ceba R, Keogh KA, Specks U, Sethi S, Fervenza FC. Rituximab for the treatment of Churg-Strauss syndrome with renal involvement. Nephrol Dial Transplant. 2011 Sep;26(9):2865-71. doi: 10.1093/ndt/gfq852. Epub 2011 Feb 16.</citation>
    <PMID>21325353</PMID>
  </results_reference>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2007</study_first_submitted>
  <study_first_submitted_qc>January 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2007</study_first_posted>
  <results_first_submitted>September 12, 2011</results_first_submitted>
  <results_first_submitted_qc>November 3, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 8, 2011</results_first_posted>
  <last_update_submitted>November 3, 2011</last_update_submitted>
  <last_update_submitted_qc>November 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Fernando Fervenza</investigator_full_name>
    <investigator_title>MD, PhD, Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Antineutrophil cytoplasmic antibody associated vasculitis</keyword>
  <keyword>Glomerulonephritis</keyword>
  <keyword>Rituximab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Churg-Strauss Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was done between June 2007 and July 2009. Participants were enrolled at the Mayo Clinic in Rochester, MN.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Rituximab</title>
          <description>375 mg/m^2/week for 4 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rituximab</title>
          <description>375 mg/m^2/week for 4 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Normalization of Eosinophil Count at 6 Months</title>
        <description>Normalization of eosinophil counts was defined as total eosinophil counts &lt;1.5 x 10^9/L.</description>
        <time_frame>6 months after beginning of remission induction regimen</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rituximab</title>
            <description>The remission induction regimen included oral prednisone and rituximab. Prednisone was started at 1 mg/kg/day for 4 weeks followed by a taper to 0 mg by 6 months. Rituximab 375 mg/m2 intravenously, once a week for 4 weeks was given within 2 weeks of starting steroid therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Normalization of Eosinophil Count at 6 Months</title>
          <description>Normalization of eosinophil counts was defined as total eosinophil counts &lt;1.5 x 10^9/L.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants With Remission of Renal Disease Activity at 3 Months</title>
        <description>Remission of renal disease activity was indicated by stable or falling creatinine, absence of active urinary sediment AND reduction of oral prednisone dose to less than 50% of average dose of preceding 3 months or less than 10 mg/day (whichever smaller)</description>
        <time_frame>3 months after beginning of remission induction regimen</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rituximab</title>
            <description>The remission induction regimen included oral prednisone and rituximab. Prednisone was started at 1 mg/kg/day for 4 weeks followed by a taper to 0 mg by 6 months. Rituximab 375 mg/m2 intravenously, once a week for 4 weeks was given within 2 weeks of starting steroid therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Remission of Renal Disease Activity at 3 Months</title>
          <description>Remission of renal disease activity was indicated by stable or falling creatinine, absence of active urinary sediment AND reduction of oral prednisone dose to less than 50% of average dose of preceding 3 months or less than 10 mg/day (whichever smaller)</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year after beginning of the remission induction regimen</time_frame>
      <desc>Safety was assessed by monitoring and recording of adverse events, defined as any untoward medical occurrences in a patient participating in the trial, regardless of causality assessment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Rituximab</title>
          <description>375 mg/m^2/week for 4 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <description>Participant was treated with oral antibiotic therapy and recovered.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The limited number of individuals enrolled into the study makes it difficult to draw firm conclusions that are more than hypothesis generating. The company providing study drug terminated study due to lack of funds.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Fernando C. Fervenza</name_or_title>
      <organization>Mayo Clinic</organization>
      <email>fervenza.fernando@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

